EDITAS MEDICINE, INC. Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction
EDITAS MEDICINE, INC. (EDIT) reported Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction of $60.00 thousand for the 9-month period ending 2015-09-30, per its 10-Q filed 2016-11-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction · last filed 2017-03-03
- EDITAS MEDICINE, INC. debt issuance costs incurred during noncash or partial noncash transaction for the quarter ending 2015-09-30 was $28.00K.
- EDITAS MEDICINE, INC. debt issuance costs incurred during noncash or partial noncash transaction for the quarter ending 2015-06-30 was $2.00K.
- EDITAS MEDICINE, INC. debt issuance costs incurred during noncash or partial noncash transaction for the quarter ending 2015-03-31 was $30.00K.
- EDITAS MEDICINE, INC. debt issuance costs incurred during noncash or partial noncash transaction for fiscal 2014 was $20.00K.
| Period end | Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction 3 month | Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction 6 month | Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction 9 month | Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction 12 month |
|---|---|---|---|---|
| 2015-09-30 | $28.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $30.00K derived: sum of 2 quarters · filed 2016-11-09 | $60.00K 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $32.00K 10-Q · filed 2016-08-10 | ||
| 2015-03-31 | $30.00K 10-Q · filed 2016-05-13 | |||
| 2014-12-31 | $20.00K 10-K · filed 2017-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |